Daniel G. TENEN

Professor Tenen is a leader in gene regulation in both normal differentiation and cancer, with a focus on leukemia, lung cancer, and liver cancer. Current efforts include basic studies understanding gene regulation in normal and leukemic hematopoietic stem cells, with an aim to develop novel ways of manipulating gene expression in stem cells as well as exploiting differences between normal and leukemic stem cells as a basis for targeted leukemia stem cell therapy, and the role of stem cell oncofetal proteins in leukemia and solid tumors, especially liver cancer.



Senior Principal Investigator, Cancer Science Institute of Singapore, NUS

Professor in Medicine, NUS

2008 – 2019 Director, Cancer Science Institute of Singapore, National University of Singapore
2008 – Present Programme Leader and Senior Principal Investigator, Cancer Science Institute of Singapore, National University of Singapore
2008 – Present Distinguished Professor in Medicine, National University of Singapore
2005 – Present Director, Blood Program, Harvard Stem Cell Institute, Harvard Medical School
1999 – Present Professor of Medicine, Harvard Medical School
1994 – 1999 Associate Professor of Medicine, Harvard Medical School
1986 – 1993 Assistant Professor of Medicine, Harvard Medical School
1978 – 1986 Instructor in Medicine, Harvard Medical School
1975 – 1984 Research Fellow in Medicine, Harvard Medical School & Dana-Farber Cancer Institute (Laboratory of David M. Livingston)

Lab Members

Selected Publications

1. Ye M, Zhang H, Yang H, Koche R, Staber PB, Cusan M, Levantini E, Welner RS, Bach CS, Zhang J, Krivtsov A, Armstrong SA, Tenen DG. Hematopoietic differentiation is required for initiation of acute myeloid leukemia. 2015. Cell Stem Cell 17:611-623.

2. Welner RS, Amabile G, Bararia D, Czibere A, Yang H, Zhang H, Pontes LF, Ye M, Levantini E, Di Ruscio A, Martinelli G, Tenen DG. Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor cells. 2015. Cancer Cell 27:671-681.

3. Amabile G*, Di Ruscio A*, Müller F*, Welner RS, Yang H, Ebralidze AK, Zhang H, Levantini E, Qi L, Martinelli G, Brummelkamp T, Le Beau MM, Figueroa ME, Bock C, Tenen DG. Dissecting the role of aberrant DNA methylation in human leukemia. 2015. Nat Commun. 6:709. *co-first authors.

4. Staber PB, Zhang P, Ye M, Welner RS, Levantini E, Di Ruscio, Ebralidze AK, Bach C, Zhang H, Zhang J, Vanura K, Delwel, Yang H, Huang G, Tenen DG. The Runx-PU.1 pathway preserves normal and AML/ETO9a leukemic stem cells. 2014. Blood 124:2391-2399. PMCID PMC4192750.

5. Di Ruscio A, Ebralidze AK, Benoukraf T, Amabile G, Goff LA, Terragni J, Figueroa ME, De Figureido Pontes LL, Alberich-Jorda M, Zhang P, Wu M, D’Alò F, Melnick A, Leone G, Ebralidze KK, Pradhan S, Rinn JL, Tenen DG. DNMT1-interacting RNAs block gene specific DNA methylation. 2013. Nature 503:371-376. PubMed Central PMCID: PMC3870304.

6. Yong KJ, Gao C, Lim JSJ, Yan B, Yang H, Dimitrov T, Kawasaki A, Ong CW, Wong KF, Lee S, Ravikumar S, Srivastava S, Tian X, Poon RT, Fan ST, Luk JM, Dan YY, Salto-Tellez M, Chai L, Tenen DG. Oncofetal Gene SALL4 Defines an Aggressive Hepatocellular Carcinoma Subtype. 2013. N Engl J Med 368:2266-76. PMCID: PMC3781214.

7. Ye M, Zhang H, Amabile G, Yang H, Staber PB, Zhang P, Levantini E, Alberich-Jordà M, Zhang J, Kawasaki A, Tenen DG. C/EBPa controls acquisition and maintenance of adult hematopoietic stem cell quiescence. 2013. Nature Cell Biol. 15:385-94. PMCID: PMC3781213.

8. Staber PB, Zhang P, Ye M, Welner R, Nombela-Arrieta C, Bach C; Kerenyi M, Bartholdy BA, Zhang H; Alberich-Jorda M, Lee S, Yang H, Ng F, Zhang J, Leddin M, Silberstein LE, Hoefler G, Gottgens B, Rosenbauer F, Huang G, Tenen DG. Sustained PU.1 Levels Balance Cell Cycle Regulators to Prevent Exhaustion of Adult Hematopoietic Stem Cells. 2013. Molecular Cell 49:934-46.

9. Amabile G, Welner RS, Nombela-Arrieta C, D’Alise AM, Di Ruscio A, Ebralidze AK, Kraytsberg Y, Ye M, Kocher O, Neuberg DS, Khrapko K, Silberstein LE, Tenen DG. In Vivo Generation of Transplantable Human Hematopoietic Cells from Induced Pluripotent Stem Cells. 2013. Blood 121:1255-64.

10. Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, Schnittger S, Behre G, Hiddemann W, Tenen DG. Dominant-negative mutations of CEBPA, encoding CCAAT/Enhancer Binding Protein-? (C/EBP?) in acute myeloid leukemia. 2001: Nature Genetics 27:263-270